CEL-SCI Corporation — FY2019 Form 10-K
Reporting period: Fiscal year ended September 30, 2019. This is an annual filing, not a standalone fourth-quarter report; quarterly Q4 results are not provided in the supplied filing text.
Business context
CEL-SCI is a clinical-stage biotechnology company with no approved products and no product-sales revenue. Its lead candidate, Multikine, is in a global Phase 3 trial for neoadjuvant treatment of advanced primary head and neck cancer. The study enrolled 928 patients by September 2016 and was following patients for outcomes. The primary endpoint requires a 10% overall-survival improvement versus standard of care; the determination depends on 298 deaths across the two main comparator groups.
LEAPS candidates, including CEL-4000 for rheumatoid arthritis, remain in preclinical development. A $1.5 million NIH SBIR grant supports development work toward an IND application.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Grant income | $463,000 | $477,000 |
| Research and development expense | $12.66 million | $10.91 million |
| General and administrative expense | $8.00 million | $6.33 million |
| Operating loss | $20.20 million | $16.77 million |
| Net loss | $22.13 million | $31.84 million |
| Basic and diluted loss per share | $0.71 | $1.87 |
| Net cash used in operating activities | $16.3 million | Not clearly stated in the supplied text |
Revenue from product sales was zero; grant income was the reported operating income source. Margins are not meaningful for this pre-commercial company. Net loss narrowed year over year, primarily alongside lower derivative-instrument losses and interest expense, while operating loss increased as R&D and administrative costs rose.
Cash and cash equivalents were $8.44 million at year-end, down from $10.31 million. Current assets were $9.81 million and current liabilities $3.02 million. Total liabilities were $22.49 million, including a $13.51 million lease financing liability and $6.49 million of derivative liabilities; the filing shows no notes payable at September 30, 2019. The company reported a $5.13 million stockholders’ equity balance, versus approximately break-even equity in 2018.
CEL-SCI raised approximately $14.8 million net in FY2019 through stock sales and warrant and option exercises. Common shares outstanding increased to 35.23 million from 28.03 million. The filing reports 5.77 million warrants and 6.22 million options outstanding at year-end.
Material changes and unusual items
- R&D expense rose about $1.7 million, including higher Phase 3 trial costs, stock compensation, and work preparing the manufacturing facility for potential commercial production.
- G&A expense rose about $1.7 million, substantially reflecting increased stock-based compensation and public-relations costs.
- Derivative losses fell to $0.76 million from $8.64 million, while net interest expense declined to $1.80 million from $4.22 million. The filing attributes the interest decline in part to conversion of all outstanding convertible notes by September 2018.
- The company reclassified approximately $1.51 million of FY2018 employee costs from G&A to R&D. It said this correction did not affect total expenses, net loss, cash flows, or equity.
- Ergomed received shares in settlement of clinical-research amounts owed. The related FY2019 non-operating gain was approximately $0.55 million; Ergomed held 198,000 shares for resale at year-end.
Outlook, risks, and contingencies
- Management estimated approximately $4.5 million of additional direct Phase 3 trial expense remained, excluding other related costs such as manufacturing. Actual cost may be higher, and timing of the final readout depends on accumulation of the required death events.
- The independent auditor included a going-concern explanatory paragraph, citing recurring losses and future liquidity needs. CEL-SCI said it expects to need additional capital; financing may come from warrant exercises, partnerships, debt, or equity, but availability and terms are uncertain. Failure to raise funds could require curtailing operations or development.
- Multikine’s efficacy and safety are unproven; a successful Phase 3 result would not itself guarantee FDA or other regulatory approval. The company also noted that the trial may not be sufficient as a U.S. pivotal study and a new Phase 3 study could be required.
- Manufacturing-facility modifications and commercial scale-up could delay a marketing application or approval. The facility lease runs through October 2028; disclosed future minimum payments under that lease total approximately $19.57 million before imputed interest.
- Principal risks include dependence on Multikine, financing and dilution, clinical and regulatory uncertainty, reliance on CROs, manufacturing and reimbursement challenges, competition, and potential adverse effects or product-liability claims. CEL-SCI reported $10 million of Multikine product-liability insurance.
- The filing reports no current legal proceedings. A 2018 arbitration award against former CRO inVentiv was paid to a litigation-finance affiliate under the funding agreement.
Most important facts for investors to verify
- Current status of the Phase 3 event count, data integrity, endpoint analysis, and timing of results; the filing gives no clear year-end event count or readout date.
- Cash runway, subsequent financing, dilution, and ability to fund trial completion and commercialization preparation.
- Whether the estimated remaining trial costs cover all obligations, given exclusions and the possibility of higher costs.
- Manufacturing-facility readiness, required modifications, regulatory inspection status, and lease-related cash commitments.
- Reconciliation of reported warrant, option, and derivative liabilities and the potential impact of further exercises or share-price changes.
- Potential effect of the disclosed Section 382 ownership change, which the company said eliminated an estimated $188.9 million of federal net operating loss carryforwards.